Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 06, 2022 16:11 ET | Source: Baudax Bio, Inc.

Baudax Bio Announces Closing of $5 Million Public Offering

MALVERN, Pa., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for hospital and related...
December 02, 2022 14:46 ET | Source: Baudax Bio, Inc.

Baudax Bio Announces Pricing of $5 Million Public Offering

MALVERN, Penn., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today...
November 30, 2022 16:50 ET | Source: Baudax Bio, Inc.

Baudax Bio Announces 1-for-40 Reverse Stock Split

MALVERN, Pa., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced that the...
November 08, 2022 16:09 ET | Source: Baudax Bio, Inc.

Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights

BX 1000 Phase II Trial Underway BX 2000 Dose Escalation Study Progressing ANJESO® Vials Sold to End Users Up 16% Third Quarter Year-Over-Year USPTO Issues Note of Allowance for additional Orange...
September 19, 2022 16:05 ET | Source: Baudax Bio, Inc.

Baudax Bio Announces Distribution of Series B Preferred Stock to Holders of its Common Stock

MALVERN, Pa., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for acute care settings,...
September 08, 2022 16:05 ET | Source: Baudax Bio, Inc.

Baudax Bio to Present at the 24th Annual H.C. Wainwright Healthcare Conference

MALVERN, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that Gerri Henwood,...
September 01, 2022 14:56 ET | Source: Baudax Bio, Inc.

Baudax Bio Announces Closing of $6.2 Million Public Offering

MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today...
August 29, 2022 22:04 ET | Source: Baudax Bio, Inc.

Baudax Bio Announces Pricing of $6.2 Million Public Offering

MALVERN, Pa., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today...
August 22, 2022 08:00 ET | Source: Baudax Bio, Inc.

Baudax Bio receives notice of allowance for U.S. Patent Application covering use of ANJESO® for the treatment of moderate to severe pain

MALVERN, Pa., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, announced today that the United States...
August 11, 2022 07:00 ET | Source: Baudax Bio, Inc.

Baudax Bio Reports Second Quarter 2022 Financial Results and Business Highlights

ANJESO® Net Product Revenue Up 49% Year-Over-Year; Vials Sold to End-Users Up 67% Year-Over-Year Dosing Complete in the First Cohort of the Phase I BX2000 Study; On Track to Complete Enrollment in...